NRX Pharmaceuticals Inc (NRXP)
3.51
-0.01
(-0.28%)
USD |
NASDAQ |
May 17, 16:00
3.51
0.00 (0.00%)
After-Hours: 20:00
NRX Pharmaceuticals Enterprise Value: 43.34M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 43.34M |
| May 16, 2024 | 43.13M |
| May 15, 2024 | 40.02M |
| May 14, 2024 | 39.49M |
| May 13, 2024 | 37.02M |
| May 10, 2024 | 37.55M |
| May 09, 2024 | 36.39M |
| May 08, 2024 | 35.23M |
| May 07, 2024 | 35.12M |
| May 06, 2024 | 37.76M |
| May 03, 2024 | 27.63M |
| May 02, 2024 | 27.20M |
| May 01, 2024 | 28.47M |
| April 30, 2024 | 32.69M |
| April 29, 2024 | 42.93M |
| April 26, 2024 | 42.59M |
| April 25, 2024 | 38.39M |
| April 24, 2024 | 38.18M |
| April 23, 2024 | 37.45M |
| April 22, 2024 | 36.92M |
| April 19, 2024 | 37.34M |
| April 18, 2024 | 35.30M |
| April 17, 2024 | 46.76M |
| April 16, 2024 | 47.95M |
| April 15, 2024 | 52.35M |
| Date | Value |
|---|---|
| April 12, 2024 | 54.46M |
| April 11, 2024 | 58.10M |
| April 10, 2024 | 58.38M |
| April 09, 2024 | 54.84M |
| April 08, 2024 | 57.90M |
| April 05, 2024 | 56.18M |
| April 04, 2024 | 55.22M |
| April 03, 2024 | 50.82M |
| April 02, 2024 | 53.31M |
| April 01, 2024 | 56.77M |
| March 28, 2024 | 49.73M |
| March 27, 2024 | 55.29M |
| March 26, 2024 | 53.95M |
| March 25, 2024 | 55.29M |
| March 22, 2024 | 56.33M |
| March 21, 2024 | 51.25M |
| March 20, 2024 | 49.40M |
| March 19, 2024 | 49.03M |
| March 18, 2024 | 52.17M |
| March 15, 2024 | 46.63M |
| March 14, 2024 | 43.94M |
| March 13, 2024 | 47.36M |
| March 12, 2024 | 45.18M |
| March 11, 2024 | 66.40M |
| March 08, 2024 | 61.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-5.828M
Minimum
Jun 16 2022
1.191B
Maximum
Jul 23 2021
158.55M
Average
43.94M
Median
Mar 14 2024
Enterprise Value Benchmarks
| Cyclacel Pharmaceuticals Inc | -0.3591M |
| Achieve Life Sciences Inc | 122.45M |
| EyePoint Pharmaceuticals Inc | 317.33M |
| Nanoviricides Inc | 19.14M |
| GlycoMimetics Inc | -11.98M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.528M |
| Total Expenses (Quarterly) | 5.998M |
| EPS Diluted (Quarterly) | -7.40 |
| Earnings Yield | -276.8% |